Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- A2 Biotherapeutics Inc.
- Study ID
- NCT04981119
- Status
- Recruiting
Conditions
- CRC
- Cancer
- Colorectal Cancer
- Head and Neck Squamous Cell Carcinoma HNSCC
- Mesothelioma
- Mesothelioma, Malignant
- Mesothelioma; Lung
- NSCLC
- Non Small Cell Lung Cancer
- Ovarian Cancer
- Ovarian Carcinoma
- Ovarian Neoplasms
- Pancreas Cancer
- Pancreatic Cancer
- Renal Cell Carcinoma (Kidney Cancer)
- Solid Tumor, Adult
- Triple Negative Breast Cancer (TNBC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Apheresis — OTHERApheresis procedure performed for collection of PBMCs.
- Next Generation Sequencing (NGS) — DIAGNOSTIC_TESTNGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
- Long Range NGS HLA typing — DIAGNOSTIC_TESTLong range NGS on whole blood to determine germline HLA type.
Study Details
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Key Dates
- Start date
- Oct 29, 2021
- Status verified
- May 2026
- Primary completion
- Dec 31, 2028
- Completion
- Apr 30, 2029
Study Design
- Enrollment
- 200 participants (estimated)
Primary Outcome Measure
Percentage of participants who can enroll in an A2 Biotherapeutics, Inc. CAR T-cell therapy study after undergoing apheresis [ Time Frame: up to 2 years ]
Central Contacts
- Clinical Trials(310)431-9180
Locations (16)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Banner Health | Gilbert | Arizona | 85234 | Matthew Ulrickson, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | Clinical Trials Referral Office 855-776-0015 Antonious Hazim, MD (PRINCIPAL_INVESTIGATOR) |
| City of Hope | Duarte | California | 90101 | - |
| University of California San Diego | La Jolla | California | 92093 | Anthony Oshmago Sandip Patel, MD (PRINCIPAL_INVESTIGATOR) |
| Stanford University | Palo Alto | California | 94304 | Vivian Leung Wen-Kai Weng, MD (PRINCIPAL_INVESTIGATOR) |
| UCLA Medical Center | Santa Monica | California | 90404 | Karla Largaespada J. Randolph Hecht, MD (PRINCIPAL_INVESTIGATOR) Edward Garon, MD (SUB_INVESTIGATOR) |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | Rhoda Romain Yanyan Lou, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| Moffitt Cancer Center | Tampa | Florida | 33136 | Katie Ehm Kedar Kirtane, MD (PRINCIPAL_INVESTIGATOR) Frederick Locke, MD (SUB_INVESTIGATOR) |
| Massachusetts General Hospital/Dana Farber Cancer Institute | Boston | Massachusetts | 02114 | - |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | Ethan Sunsvold Julian Molina, MD, PhD (PRINCIPAL_INVESTIGATOR) Yi Lin, MD, PhD (SUB_INVESTIGATOR) |
| Washington University | St Louis | Missouri | 63110 | Hussain Hassan Patrick Grierson, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| NYU Langone Medical Center | New York | New York | 10016 | Kennedi Rainey Kristen Spencer, DO (PRINCIPAL_INVESTIGATOR) |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Jinesh Gheeya, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Cathy Eng, M.D., FACP, FASCO (PRINCIPAL_INVESTIGATOR) |
| MD Anderson Cancer Center | Houston | Texas | 77030 | - |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Shelby Colden Jennifer Specht, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Gilbert, AZ
Related Studies
- Data Collection for Patients With Low Grade Ovarian or Peritoneal TumorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruiting · M.D. Anderson Cancer Center · Miami, Florida
- Establishment of a Lifetime of Cohort of Adults Surviving Childhood CancerRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruiting · Mayo Clinic · Phoenix, Arizona